A human Campylobacter jejllni infection model provided controlled exposure to assess vaccine efficacy and investigate protective immunity for this important diarrheal pathogen. A well-characterized outbreak strain, C.jejuni 81-176, was investigated using a volunteer experimental infection model to evaluate the dose range and duration ol' protection. Henlthy Campylobacter-seronegn tive adults received C. jejuni struin 81-176 via oral inoculation nf 10 5 , 10 7 , or 10 9 CFU (5 adults/dose), which was follnwed hy clinical and imnmnnlngical monitoring. Uased on dose range clinical outcomes, the 10 9 -CFU dose (II= 31) was used to assess homologous protection at 28 to 49 days (short-term veterans [S'IV]; n = 8) or 1 year (long-term veterans [L1V];" = 7)
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pled with predefined endpoints to assess the eOkacy of a candidate vaccine and to investigate pathogenesis and immunity. C . jejuni 81-176, a milk-borne outbreak strain (26) , was one of the two strains investigated. This study documented the pathogenicity of C. jcjuni; however, low and variable rates of attack (40 to 60%) without an illness dose response (10 6 to lO<J CFU delivered in skim milk) were observed (Sa, 7). Infection with or without illness induced serologic and intestinal antihody responses. Higher prechallenge C. je,iunispecific (acid-extracted protein) serologic and jejunal fluid IgA levels in noninfected subjects than in infected subjects were observed, as were increased levels of jejunal fluid lgA during rechallenge in subjects who remained well after a second exposure.
A rare (approximately I in 1,000 to 3,000 C. jejuni enteritis cases [30, 42] ) but potentially life-threatening complication of Campylobactcr infection is Guillain-Barrc syndrome (GBS), a postinfectious polyneuropathy that is a leading cause of paralysis (32, 49) . Research evidence supports the hypothesis that the C. jejuni-GBS association is due to molecular mimicry, where peripheral nerve gangliosides share epitopes with C. jejuni outer lipooligosaccharidc (LOS) cores, leading to a misdirected and harmful immune response (17, 25, 53, 54) . Prestudy characterization of the challenge strain revealed no evidence of ganglioside mimicry associated with GBS pathogenesis (12) .
The campylobacteriosis clinical outcomes observed in the study of Black et al. were not sufficiently frequent or predictable based on the dose to support evaluation of vaccine efficacy. In the current study. two modifications were included, inoculum delivery with bicarbonate buffer and C. jeju11i-specific serologic screening, hased on post hoc analysis of data from the previous study (3) . The change in the method of inoculum delivery was based on evidence obtained with a human Shigella infection model, which showed that 11/12 (92%) nai've subjects developed clinical illness when 1.4 X 10 3 CFU was delivered with bicarbonate buffer (2 g NaHC0 3 in 150 ml distilled water), compared to attack rates of 50 to 60% (upper limits) with challenge doses between 5 x 10 3 and 1 x 10 8 CFU in skim milk in previous studies (27) .
In this study we report a refined human C. jejuni 81-176 infection model which demonstrated that there was a doserdatcd increase in campylohactcriosis rates and provided evidence of complete short-term protection that waned with time and cell-mediated immune response patterns that were associated with protection. This work improves the model for future application and provides directions for additional refinements.
(This study was presented in part at the lOth International Congress of Immunology, New Delhi, India, 1998, and at the lOth International Workshop on Campylobacter, Helicobacter and Related Organisms, Baltimore, MD, 1999.)
MATERW-'i AND M._IHODS Study de!llgn. 'Il1is study included three stages: a dose range analysis ( ]()·", llf. and 10 9 CFU; 5 subjects/group), confirmation of the selected dose (10 9 CFU) with moderately severe (2:70%) target campylobacteriosis, and homologous challenge. Subjects were rechallenged I to 2 mo111hs (short-term veterans [S1V)) or 1 yl!ar (long-lerm veterans [L"'V]) after thc first infcction.
Purticipants und subjel1 eligibility. Hcallhy ildults (ages. 18 to 55 years) were recruit!!d frum the! grcater Washington. DC, arca and cnrollcd aftl!r inftlrmcd l'Onscnt was obtained. l11c criteria for exclusion included pt.lor health: personal or family history of C. iUS or inflammatory arthriti.o;; macrolide or Huofl\quinuhmr allergy; commercial food handler; clinically ~ignificanr ahnonnalilie~ a~ dl!lermined by physical examination or basic laboratory screening (complele bloml coulll, serum chemistry. urinalysis, HIV-1 enzyme-linked irnrnunosorbenl assay [EUSAJ. hepatitis H surfal'C antigen. hcpatitis C virus ELISA. HLA-H27. and scmm prcgnant:y rest); abnormal bowel habits; regular usc of antidiarrheal llf amiconstipation agent: antacid therapy: antibiotic usc (7 days before admission); LLo;e of immunosuppressive drugs; and 11articiparinn in research involving another investigational product. Prior exposure to Cumpylvbacu•r, as determined hy history or serology (C. jejuni glycine extract lgA ELISA absorbanre al 405 nm of >0.5 at 1:1,000 dilution, has~d on a pr~vious report [3) ), was also a basis for c:xclusion.
Chun1ctea·izutiou of C. jrjuni stmin. C. jc,iuni 81-176 (Pcnn~r serotype 2J/36) was isolated from u child with watery diarrhea during a milk-horne outhrc:ak (26) and was used in a previous challenge study (7) . An isolarc rel'overcd from a subject with diarrhl!a was used to prepare a master seed lot at the Walter Reed Army Institute of Rcs~arch Pilot DioProdurtion Facility (preseJVed in l5o/c. glycerol at -85°C). The: chalh:nge strain is susu:priblc! to macrolidcs and fluuroquinolones.
I•rcparution and delivery or chullcngc inocula. Challenge inocula wen: prepared from the ma.o;ter secd ~lock a~ previou!'ly dcscrih~d (7). except that Muc:ller-Himon soft agar was uSI!d to sekct fur highly motile C. jejuni cells, which were ptlOied and subcultured on /Jrucella agar (Difco. Detroit. Ml). Confluent growth was harvcst..:d in cold phosphate-buffered saline (I'BS). and the uptil:al density at 625 nm (OD..,2.,) was adjusted Ill the apprtlpriatc rargct value (postinlX:ulatiun number of CFU as d~t~rmined by plate counting). A 5-ml aliquot was mixed with ISO ml of sterile: water l'Ontaining 2 g of sodium hicarhonate and thc:n ingc:sted with 90 min of fasting heforc and after inoeulatillll. Dose selection. randomization, and blinding procedures. Subjects were randomly assigned to groups during the dos~ range double-blinded phase. After the dose range phase. th~ study wus unblindcd to allow sclc..:tion of the dllSO.: us~d for suhsequent studies.
Clinlrul outcome definitions. lnf~ction was defined as twu eons~cutiw C.
jeJuni-positive stool cultures ~::!4 h after oral ino~:ulation. Diarrhea was dc· fined as 2'::3 loose or liquid stools ~1cr 24-h period ur ~2 loose or liquid stools with a volume <dOO ml in a 24-h period. The associated symplnms included in the clinical grading proc~dure were fever (2:38.1°C), abdominal cramps. nausea. vomiting, tenesmus. and dysentery (gross blood in two specimens), anti the following scale was used: gratle U, not present; grade l, mild. barely noticed; grade 2, mmlcratc. easily noticed, with some change in normal activities: and grade ~.severe, unable to perform normal activities. Campy· lobacteriosis. the primary ~ndpoint, was de lined :1s documented infecti•>n and clinical illness thntoccurrcll prior to the lirst dose of antihil>Lic. The ..:ampylobactcriosis categories used w~rc mild (diarrhea with no as!'ociat~d symptom greater than grade 1 ), moderate (any two uf the following indications: diar· rhea, fever. one or more grade 2 associated symptoms. and one grade 3 associated symptom), and severo: (any two of the following indic;uions: diarrhea with a total of >I} stools. dysentery. high fever I>~R.fi 0 CJ, and more than one grade 3 associated symptum).
Clinical monitoring and manugement. Subjects were evaluated daily while they were in a rcstrktcd-ac~:~ss inpatio.:m ward until they were cleared for discharge following antihiotic therapy and resolution of clinical illn~ss. Any !'uhjcct who develop.:d diarrhea rec~ivcd appropriate oral rehydration (intravenous if needed). All subjects rel·eived azithromycin (500 mg orally onU! a day for 5 days) irrespective of the infcetkm or illness status 5 days after ino~:ulation (the antibiotic start day was extended lo day 7 for lhc LIV group). The subjects who met criteria for severe campylohilcteriosis were treated immediately. whereao; the other subjects rcl·ciwd treatment 72 h after the onset of illness. WC~:kly clinical visits oc~:urrcd until day 28 pustinlll"ulation Ill assess eviden~:c uf relapse anll postinfcction sequelae.
Stool microbiulogy. Routine stool hal·tc:riology and parasituklgy studies were performed I week before admission. During the inpatient period. sloc.,ls were evaluated to determine their volume. stool grade, visible and tlCcuh bloud, and fecal lcukO'-)'to.:s (l)ncc a day for diarrheal stool~). ( 4, 5) . Stool samples were kept on il.-c, and 2-to 4-g aliquots were frozen within 10 h after collection at -71rC before processing.
(ii) Serology. Campylohuctt•r glycine extract (GE)-specific serum antibodies were measured by ELISA using peroxidase-conjugated i~oiYJlC-specific goat antihuman immunoglobulins as described elsewhere (.5 . J4). Endpoint liters were calculated by determining the reciprocal of the! highest dilution that gave a net (antigen well -L'Ontrol well) absorllance of ~0. 15 . Endpoint titers were lo&c transfonned and expressed as geometric mean titers.
(iii) ASC. Levels of antibody-secreting (."ells (ASC) were determined by using the enzyme-linked immunosorbent spot-forming assay described elsewhere (3). Nunc immunoplates were coated with 3 tJ.g/ml of GE in pH !:1.6 buffer. The
PMBCs were washed and susrended at a concentration llf 3.33 x 10 6 cells/ml in compleh: medium (CM) (lU'MI containing 10% heat-inactivated fetal calf serum, 2 mM •-glutamine. and 50 IJ.g/ml gentamicin). Following 4 h of incubation with PBMO; (3.33 -< 10"~ PBMCsiwcll in triplicate). the SCl'rcted antibodies were detected with alkaline phosphatase-conjugated goat anti-human lgA (£1.2.~ IJ.g/ml; KPL. Gaithersburg. MD). Spots were visualized with nitroblue tetrazolium (10 tJ.g/ml)-5-bromo-4-chlom-3-indolylphosphat e (BCIP) (5 IJ.g/ml) (Sigma Chemicals, MO) in 0.6% agaroSI.! and counted with a diss~:cting scope. A sampl~: with ~5 ASOHr PBMCs was considered a responder sample.
(iv) Fecal lgA. A I 0% stool suspension was prepared in hulfer containing protea.-.e inhibitors <n incullated fur 20 min at 4°C, and (."entrifuged, and the supernatant was frozen at -7£rC. The total IgA content was determined by an EUSA using goat anti-human f(ab'h ( 1 11Wml; Jackson Laboratories) as the capture: antibody and isotype-spedlic horseradish peroxidase-conjugated goat anti-human lgA as the detct:ting antibody (22, 34) . The Campylobat·ter-spcc:ific lg.A content was determined by the EUSA described above, except that the incubation time was 3 h. Endpoint titers were determined and adjusted to .500 IJ.g/ml of total IgA: samples with <50 IJ.g/ml total IgA were excluded.
(v) JFN-y assay. PBMCs were washed and suspended at a concentration of 5 x H}~ viable cells/mluf CM (RPMI ctmtaining 10% heat-inactivated human AB Sl.!rum, 2 mM L-glutaminc, 5 X w-7 mM 2-men.:aptocthanol, and 50 l!g/ml gentamicin). Twenty micmlitcrs of medium alone or medium L"Ontaining 10~ formalin-killed C. jejrmi 81-176 whok cells in addition to 200 Ill of CM containing to-~ PBMCs was added to wells of wund-hottum %-well tissue plates in duplicate. Following 72 h of incubation at 37°C in 5% C0 2 , supernatants were collected and shJred at -7ooc until they were assayed to determine the gamma interferon (IFN-y) levels by a capture ELISA using paired monoclonal antibodies. and the levels were interpolated using knuwn standards (Endogcn, Wohurn, MA).
(vi) CRP. The C-reactivc protein (CRP) content of plasma samples was dctemlined using a commercial kit (Dade Behring, Marburg, Germany). Data are expressed below in micrograms of CRP per milliliter: samples containing <6 tJ.g/ml ofCRPwerc: considered negative. and the concentrations in these samples were consideretl 3 IJ.giml.
Statistical analysis. Baseline characteristics and summary findings were compared using analysis of variance, Kru~kal-Wallis tests. and chi-square tests. as appropriate. Confidence intervals (CI) were generated using a normal approximation to the binomial distribution. Times to events were evaluated using Kaplan-Meier analyses. All tests were two tailed. and I' values of <0.05 were l'Onsidercd statistically significant. Statistical analyses wl!rl! performl!d using SPSS for Windows (version 10.1).
RESULTS
Subject enrollment and baseline characteristics. Following consent, subjects were enrolled; members of the na"ive group received 10 5 CFU (n = 5), 10 7 CFU (n = 5). or 10 9 CFU (n = 36), and STV (n = 8) and LTV (fl = 7) received 10<) CFU. There were no differences in demographic characteristics among the groups. The median age of the naive subjects was 30 years (interquartile range [JQR], 22.0 jejuni . 1l1e S1V and L1V groups are described in Materials and MethPd~. For vl!terans the c.:linical outwmcs after the initial exposure werl! as follows: for the S1V group, one subject wilh mild campylnhacteriosis. three subjects with modl!rate campyk,bactcriosis, and four subjects with ~vcre campylubacterio~is; and for the LTV group, thrc:e subjel·ts that did no1 mec:l th~: dinkal c:ndpoint (after the initial exposure, rwo ~uhjects with moderate l'ampy!Phacteriosis and one subject who was not ill) and four subjects with campylobactcriosis raftl!r the initial exposure. one subject who was not ill and three subjects with severe campylohacteriosi~).
b Inf~:ction was defined as tWll cunsc.:cutivc Stlllll cultures that were positive for C jejuni at ~24 h postinoculation.
c The levels of campylobactcriosis were defined as follows (all required dl'C· umcntation lJf infection). Mild campyllJllaclcriosis was llclincd as 3 to 9 loose l'r liquid stools per 24 h ur a::2 loose Sllluls per 24 h consisting nf a::J(I(l mi. Moderate campylobacteriusis was delincd as IWlltlf the flllluwing: diarrhea, oral temperature of :::38.1°C, and moderate ur severe gastrointestinal signs or symptoms (abdominaJ~.·ramps. nausea. vomiting. tenesmus. and gross blood in stools). Severe campylobacteriosis was delined as an)· two of the foll .. lwing plus infet:tion: high fever (oral temperature, >JSNC), diarrhea ( >9 swols), >I ~ever..: a~suci atcd symptom. and dysl!nteric Shlols (gross blood in two specimens).
'
1 The campylobacteriosis attack rates were different fur the vetl!ran groups
~The numbers of subjects tested fur fecal lcukn~-ytc:s were: as follows: 4 subjects wh'' received I(}~ CFU. ~ suhject~ who rcl·civcd 10 7 C"FU. all naive ~ubjl!l"ts whu received 10
11 CFU, and all suhjccts in the veteran gwup~.
to 42.0 years): the majority of tht! subjects were males (70c~; and 80%, respectively). Clinical outcomes. A dose-related incrt!ase in the incidence of campylobacteriosis of any severity was observed for nai"ve subjects (P = 0.006). No dose relationship was observed for associated symptoms or for meeting criteria for severe campylobactcriosis (Table 1 ) : however, compared to the results obtained with lower doses, the total volume of diarrhea was 3-fold greater for the group that received 10'' CFU (means. 462 ml and 1.469 ml; P = 0.0 J) (Fig. I) . The maximum illness severity index (Sf), as shown in Fig. 1 , provided a composite semiquantitative score that accounted for gastrointestinal and systemic features. The median scores were similar for the groups that received 10 5 and 10'' CFU; however, the scores for 2.1% of the subjects in the group that received 10 9 CFU were greater than 12. compareu to 10% of the subjects in the groups 
2S
: rll ::. 0 ~u _a.;: , and 10 9 CFU and STV and LTV who received 10 9 CFU. The box plots show medians, intcrquartilc ranges. and minimum and maximum values. The lirsl diarrheal stool was the first louse or liquid stool fulfilling the definition of diarrhea. Clearance data were based on the time of the last C. jejuni-positive stool culture (time zero was the time when the first antibiotic dose was given). The illness severity index (SI) was calculated using gastrointestinal symptoms (abdominal cramps, nausea, vomiting, tenesmus, and dysentery), systemic symptoms (chills and sweats, malaise, joint aches, loss of appetite. and headache), the maximum temperature, and diarrhea (highest value for stool frequency or volume over the illness episode). The composite score was calculated as follows: symptom score (0, no symptoms; I. grade I symptoms; 2, grade 2 symptoms; 3, 1 or 2 grade 3 symptoms; 4, ~3 grade 3 symptoms) plus the maximum temperature score (0. <38.1°C; 1. 38 .1 to 38.3°C; 2. 38.4 to 38.6°C; 3. 38.7 to 38.8°C; 4. >38.8°C) plus tht: diarrhea score (0. no loose or liquid stools; 1, <3 stools or <:mn rnl; 2, 3 to 6 stools or 500 to 999 ml; 3, 7 to 9 stools or 1,000 to 1,499 ml; 4, >9 stools or > 1,500 ml). The Sl ranged from 0 to 16. Tht: P values for comparisons of naive subjects who received 10') CFU and subjects who received lower dost:s were as follows: fur median incubation time, Urcsluw P = 0.0198 and lug rank P = 0.0038; and for median time tu infcl·tion. Urcslow /' = 0.0004 and log rank P = 0. 0003. that received lower doses. Early treatment was more common in the group that received 10 9 CFU (61 %, compared to 10% for the groups that received lower doses).
With the same dose, 92% of the naiVe subjects, none of the STV, and 57% of the LTV met the campylobacteriosis endpoint (Table 1 ) . STV were not completely asymptomatic (median SI. 0: IQR, 0 to 2.75) (Fig. 1) . LTV had reduced attack rates compared to the na'ive subjects who received J 0 9 CFU (57% and 92%, respectively; P = 0.045). However, the median Sis (6[IQR, 3 to 9] and 8[IQR, 4 to 12.75], respectively) were not statistically significantly different (P = 0.24). The reduced severity in LTV was evident because there was less fever and severe campylobacteriosis (14c%, of the subjects for both, compared with 44% ). The median duration of diarrhea after the first antibiotic dose for LTV was -43 h (diarrhea resolved >1.5 days prior to antihiotic treatment), compared to 10 h after the first dose for naiVe subjects. The time to onset of diarrhea was significantly shorter for the group that received 1 O" CFU than for the groups that received the lower doses; the median incubation times were 21 .0 h (95% confidence interval [CI], 16.9 to 25.5 h) and 71.1 h (95% CI, 33.8 to 108.3 h), respectively (Fig. 1) . Similar incubation times were observed for na'ive subjects and long-term veterans. The range of duration of diarrhea was wider for the na'ivc group that receive(.) 10') CFU, primarily due to earlier onset and slower recovery.
Higher rates of hemoccult positivity and fecal leukocytes were observed for nai've subjects who received the lower doses (Table 1) . Compared to LTV (43%) and the na·ive suhjccts who received the lower doses, STV had no detectable positive hemoccuh. Fecal leukocytes were uncommon in the veteran groups. The peripheral blood median white blood cell counts (2 days postinoculation), determined only for naiVe subjects and STV, were within the normal range; however, leukocytosis (> 10,000 cells/mm-') occurred in 20t~, of the subjects who received 10 5 and 10 9 CFU (highest level, 17,000 cells/mm 3 in subjects who received 101) CFU). The median peak CRP values were similar (24 to 48) irrespective of the dose for the nai've groups, and these levels were higher than those for citht:r veteran group (3 to 6).
Microbiology results. All na-..ve and LTV subjects became infected, whereas 2 of 8 STV did not become infected (Table  1) The median time tu infection was shorter for na'ive subjects who received 10 9 CFU (18.9 h; 95% CI, 9.8 to 28.0 h) than for naive subjects who received lower doses ( 43.8 h; 95% CI, 34 .0 to 53.7 h) (Fig. I) . The time to infection for veterans was similar to the time to infection fur nai've subjects who received 10 9 CFU (for STV, 20.3 h IYS% CI, Il.4 to 29.2 h; for LTV. 8.9 h [95% Cl, 4.5to 13.3 h). The time to clearance (Fig. 1) was dependent on antibiotic usage, with the exception of the time to clearance for short-term veterans. who cleared their infections prior to antibiotic treatment.
Immunological responses. A detailed immunological analysis of acquired mucosal and systemic humoral and cellular immunity to Campylobacter was conducted. Increasing doses of C. jejuni (over a 4-lug range) were not significantly associated with higher levels of Campylobacter-specitk serum immunoglobulins in naive subjects. In addition to the levels, the kindics of serum responses and the responder rates were indistinguishable for the dill"erenl doses (Fig. 2 ) (7S to 80% for lgM, 75 to 100% for lgA, and 60 to 64% for IgG). In na'ive subjects, the level of IgG increased gradually and remained above the baseline level during the study period (except for the group that received 10 7 CFU). Compared to the level of lgG, the level of serum lgA or IgM was lower and tended to decline from study day 21 to study day oO. Overall, veterans had higher baseline serum antibody levels than nai've subjects; however, only lgG levels were significantly higher in STV (P = 0.003). Following rechallenge, no increase in antibody levels in STV wali detected; however, LTV exhihitcd early increased IgM levels (peak at day 10, compared to day 21 for naive subjects) and increased lgA levels (P = 0.02).
The level of antigen-specific ASC in circulation was detamined as a surrogate marker for mucosal immune activation. After inoculation Campylobacler-specirlc IgA-speciric ASC were detected in all nai've subjects and LTV, and the maximum median concentrations were 220, 260, 281, and 135 ASC/10 6 PBMCs for the na'ive groups that received 10 5 , 10 7 , and 10() CFU and the LTV group, respectively (Fig. 3) . In contrast, only 2 of 8 STV had detectable levels of lgA-specific ASC (8 and 32 ASC/lOh PBMCs).
The amount of Campvlohacter-specilk fecal lgA in stools collected before and after infection was evaluated as a direct measure of the intestinal antibody response (Fig. 4 ) . Compared to the levels for naive subjects, the baseline fecal lgA levels were higher for the veteran groups (P < 0.0001 ), and detectable levels (endpoint tilers. > 1.5) were found in 20%, 75%, and 67% of the nai've subjects. STV, and LTV, respectively (P = O.OOI). Irrespective of the dose. robust fecal lgA responses were observed in 86 to 100% of na'ivc subjects; these VoL. 78 responses peaked between days 7 and 9 and remained elevated. The responder rates, as well as the maximum titers postchallenge, were higher for LTV than for STV (responder rates, 83 and 63%, respectively; median endpoint titers for STV, 471 and 184, respectively; P = 0.014). A difference in the kinetics of the fecal IgA response determined by the responder rates was noted. At day 4, 24% of the nai'vc subjects, 38% of the STV, and 67% of the LTV exhibited a 2=4-fold increase in the fecal IgA level compared with the baseline level.
The in Pitro induction of IFN--y by CamP.vlobacter-stimulated PBMCs was measured as an indicator of cellular immunity. Although the baseline median levels of IFN--y in na'ive subjects were similar (60 pg/ml: IQR, 2.5 to 212 pg/ml), the individual levels varied widely (Fig. 5) . In contrast to the humoral responses, dose-dependent increases in the IFN--y level and the frequency of responders (2:4-fold increase) were obseiVed (medians for the groups that received <10 9 CFU, 669 pg/ml and 63% responders; medians for the group that received 10 9 CFU, 1,495 pg/ml and 86% responders). Compared to the baseline levels for the na'ive subjects. the baseline levels were higher for veterans (P < 0.0001). The median levels postinfection for the STV, LTV, and nai've groups that received 10 9 CFU were 2,951, 3,229, and 8,54 pg/ml, respectively (P = 0.037). There was a wide spectrum of maximum changes, which tended toward higher values for the na'ive subjects (negative change, 3%; 1 to 1.000 pg/ml, 37%; >1,000 pg/ml, 60%) than for the STV subjects (negative change, 57%; 1 to 1,000 pg/ml, none; >1,000 pg/ml, 43%) and the LTV subjects (negative change, 14%; 1 to 1,000 pg/ml, 43':if-; > 1,000 pg/ml, 43%) (P < O.OOCH).
The nai've subjects who received I 0 9 CFU of C. jejuni and the veteran groups were used to assess the association between immunological parameters and disease outcome following challenge (Table 2) . ASC and serologic levels at the time of challenge were not associated with the clinical outcome. Prechallenge Campylobacter-spccitic fecal lgA levels were not associated with disease outcome; however, the subsequent response in the nai"ve subjects with severe disease was lower than the response in the na·ive subjects with disease that was not severe (33-and 378-fold increases, respectively; P = 0.004). Prechallenge in vitro production of IFN--y correlated with disease outcome. The subjects who remained asymptomatic irrespective of exposure history had higher IFN--y levels (5,378, 2,465, and 6,003 pg/ml in nai've subjects, STV, and LTV, respectively) at the time of challenge than the individuals who had severe disease ( 49 and 17 pg/ml in na'ive subjects and LTV, respectively; P < 0.000 I). Two of the three nai"ve subjects and three LTV subjects who were protected from illness had IFN--y levels of > 2,000 pg/ml: one LTV who met severe illness criteria had the lowest level ( 17 pglml). A prechallengc IFN--y level of ~400 pg/ml was observed for the upper 15% of the subjects. This threshold level could be used to predict the likelihood of subsequent illness; the incitlcnce of campylobacteriosis was 74% among subjects with prechallenge IFN--y levels of <400 pg/ml, and the incitlence of illness was 17'Yt) among suhjccts with prcchallenge IFN--y levels o[ 2:400 pg/ml (P < 0.0001 ). Further, when the analysis was restricted to LTV and na'ive subjects, the results demonstrated that the an IFN--y level of 2:400 pg/ml was associated with protection (55% compared with 17%) (P = 0.009).
DISCUSSION
These studies confirmed and extended previous work by Black et al. that established a C. jejmzi infection model in humans (Sa, 7). As in the previous study, C. jejuni strain 81-176 exhibitetl 100% infectivity across the range of doses and a clinical spectrum of illness, consistent with clinical obseiVations (8), ranging from mild watery diarrh~a to dysentery with fever and abdominal cramps. No dysentery was obseiVed in a milk-borne outbreak caused by this strain (26) . Methodological changes, including inoculation with bicarbonate buffer and serologic screening, led to a dose response that included 92% campylobacteriosis at the highest dose ( 1 x 10 9 CFU). compared to a maximum of bO% illness in the previous challenge study. A dose response was observed during the outbreak based on the number of glasses of raw milk ingested (no milk, 0/20 subjects who were ill; 1 glass of milk. 35% ill subjects; ~2 glasses of milk, 60% ill subjects) (26) . Dose-response modeling to reconcile outbreak and experimental infection data supported the hypothesis that a very low dose (50% infectious dose, s 10 2 CFU) is capable of causing infection am.l illness (47) .
The incubation period for the 10 9 -CFU dose (21 h) was less than the incubation period for lower doses (71 h). the incubation period determined in a previous study (53 h) (7), the incubation period determined in an investigation of an outbreak (68 h; range, 24 to 128 h) (26) , and the incubation period for campylobacteriosis in general (14) . Subjects who received the highest dost! exhibitt!d more severe clinical symptoms than subjects who received lower doses, as measured by higher total stool volume, and 25% of these subjects were in the highest severity index quartile.
Short-term protection from illness was observed, confirming a previous observation (7 ) . In addition, 25% of the subjects were not infected. and the inrected subjects exhibited 3-logIower maximum excretion than naiVe subjects or LTV. providing direct evidence that acquired immunity leads to resistance to colonization in addition to protection from illness not observed in the previous challenge study. Another important new observation is that partial protection at 1 year was shown by lower attack rates and milder disease with no effect on the infection status or level of colonization. Epidemiological evidence from developing countries (29, 40, 44, 45) and industrialized countries (Sa) supports the hypothesis that protective immunity is likely acquired after repeated exposure to various strains. The change from illness tl, infection in early childhood followed by asymptomatic colonization (15, 16, 38, 43) , the shorter excretion period in highcr-incidt!ncc regions (24, 44) . the lower incidence after repeated consumption of raw milk (11 ), and the emergence of less common serotypcs in elderly populations (31) suggest that protection is long lasting, in contrast to the waning homologous protection observed at 1 year in this study, which may have been due to less background exposure to C. jejuni. There is limited comparative data from challenge studies to assess the duration of protection; however, infectionderived protective immunity to Vibrio dw/erae persisted for 3 years (2X).
The rates of robust systemic and mucosal immunt! responses observed after infection in virtually all na'ive subjects were comparable to or higher than the rates observed after natural exposure to C. jejuni (5, 21, 35. 41. 48) . Epidemiological evidence also supports the conclusion that the serum antibody level is associated with protection, as previously discussed; however, this association was not observed for challenges of veterans (although all STV had sustained high serum antibody ~ ~ levels following primary infection). The mucosal immune response patterns were different for different veterans, providing insight into effector responses that prevent and/or attenuate illness. In the protected STY the intestinal lgA levels were marginally boosted without circulating ASCs, likely renecting effective local mucosal effector responses (23, 50). In conrrast, LTV, who exhibited an attenuated and self-resolving illness, exhibited ASC responses comparable to those obscJVcd in subjccts with primary infection but. most importantly, morc rapid anamnestic fecal lgA responses (day 4) and greater lgA and JgM serologic responses than naive subjects, likcly contributing to rapid recovery from illness. In addition to distinct patterns. the modcl provides important cvidencc that C. jejuni-specific cell-mediated immune (CMI) responses correlate with protection, with in vitro IFN-'Y lcvcls of 2::400 pg/ml prechallenge yielding a relative risk of campylobactaiosis of 0.36 (95% CI, 0.24 to 0.55)./n vitro data (20, 21 ) , animal modcl data (39) and dinicalobseJVations, colitis biopsy data (37) , and a higher risk in HIV/AJDS patients (33, 4o) support the hypothesis that CMI has a primary role in C. jejwzi clearance with TH I polarization.
Major considerations in a Campylobacter challenge study include safety, management of acutc illness, and the pOlential for postinfection sequelae. GllS is a rare disease. and C. jcjuni infcction is the most common antecedent event (14) . Given the sevcrity of this illness, strain 81-176 was characterized to rule out the possibility of ganglioside mimicry before rhe study proceedcd (36) . Following the study, further genetic analysis of the 81-176 WS core revealed ganglioside mimics (IX). Thus. strain 81-17o may pose a prcviously unrecognized risk for subjects. Campvlobacter strains thar lack mimicry have been described. and usc of thcsc strains in the model would furthcr mitigate risk. Additional revision of the challenge model is needed to obtain artack ratcs comparablc to thosc seen with 10., CFU using lower doses and to target moderate to severe clinical illness and a more typical illness onset time. Addition of cellular memory response screening has rhe potential to improve selection of nai"vc subjects. rcsulting in a morc uniform and predictable attack rate for evaluation of vaccine efficacy. As reccntly described in an excellcnt rcview ( 19) , appropriate interpretation of epidemiological and risk assessment studies depends on an improved understanding of the imerplay and dynamics of protective immunity in campylobacteriosis ar both thc individual and population levels. This wMk increased our understanding of the duration of homologous protection in campylobacteriosis and provided further information on adaptive immune responses associated with protection.
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